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Objective: Circulating osteoglycin may facilitate the crosstalk between bone and
pancreas to empower adaptation of bone mass to whole body energy balance. We
aimed to examine whether osteoglycin is associated with bone and metabolic parameters
and if osteoglycin levels differ between patients with type 1 and 2 diabetes (T1D and T2D).
Design and methods: A cross-sectional study of 190 patients with diabetes mellitus
and stable hemoglobin A1c (HbA1c) (97 T1D and 93 T2D) was conducted. S-
osteoglycin was analyzed by ELISA. Unpaired t-tests were performed to test
differences between patients with T1D and T2D and linear regression analyses were
performed to investigate associations between osteoglycin, glycemic markers, bone
turnover markers and characteristics.
Results: S-osteoglycin did not differ between patients with T1D and T2D (p=0.10). No
associations were present between osteoglycin and age, gender, microvascular
complications, HbA1c, or plasma glucose in T1D or T2D patients (p>0.05 for all). S-
osteoglycin was not associated with levels of bone turnover markers (C-terminal cross-
linked telopeptide of type-I collagen (CTX), P-procollagen type 1 amino terminal
propeptide (P1NP), P-osteocalcin (OC), P-sclerostin, S-osteoprotegerin (OPG) or S-
Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL)) in neither T1D or
T2D patients (p>0.05 for all).
Conclusion:Osteoglycin levels were similar in T1D and T2D patients. Osteoglycin did not
correlate with glucose, HbA1c or any other biochemical marker of bone turnover. Thus,
we did not find evidence supporting the existence of an osteoglycin-bone-pancreas axis.
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT01870557.
Keywords: bone, diabetes mellitus, osteoglycin, hyperglycemia, bone turnovern.org March 2021 | Volume 12 | Article 6497181
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Diabetes mellitus (DM) is a chronic metabolic derangement
often leading to serious complications that may affect multiple
organs (1). Recently, it has become evident that diabetes is
associated with increased risk of fractures that cannot be
explained by reduced areal bone mineral density (aBMD) (2, 3).
Bone turnover is reported to be lower in patients with T2D
compared to T1D (4, 5). Markers of bone turnover has expanded
over the last decade and include a number of suggested potential
markers to be used in a clinical setting in addition to aBMD (6).
Osteoglycin is a proteoglycan rich in leucine which derives
from bone, cartilage and myocytes, and can be detected in serum
(7–9). Osteoglycin enhance bone mineralization and formation
by stimulating alkaline phosphatase and osteocalcin mRNA in
osteoblasts examined in vitro (6, 10). Furthermore, osteoglycin
expression by myoblast is increased by addition of active 1,25
Vitamin D (10, 11). Osteoglycin is hypothesized to have
endocrine effects on bone and pancreas. Osteoglycin knockout
mice displayed increasing amounts of white adipose tissue and
impaired glucose tolerance independent of diet consumption
(12). Another study reported higher femoral bone mineral
content and abnormal increased size of collagen fibrils in
osteoglycin deficient mice compared to wild type littermates
(13). The increased bone mass in osteoglycin deficient mice
suggest osteoglycin to reduce osteoblast activity by down-stream
mediation of Y1 receptor signaling, resulting in an increased
number of osteoclasts and impaired mineralization (12). Also,
treatment with osteoglycin in mice was related to lowering of
blood glucose in a dose dependent manner as well as potentiating
lowering of glucose during insulin tolerance test (12).
Human studies investigating osteoglycin are sparse.
Osteoglycin was more abundant in visceral adipose tissue
compared to white adipose tissue in overweight human subjects
(14). In postmenopausal women with T2D, osteoglycin levels are
associated with duration of diabetes, decreased aBMD and
presence of vertebral fractures but not N-terminal cross-linked
telopeptide of type-I collagen (NTX), osteocalcin (OC), fasting
glucose or HbA1c (15). These findings suggest osteoglycin to be a
marker of low aBMD and vertebral fractures in T2D.
Examination of S-osteoglycin in humans following gastric
surgery showed negative correlation with body mass index (BMI)
and positive correlation with lean body mass as well as increasing
levels of S-osteoglycin during weight loss (12). However, gastric
surgery itself may impact bone health and metabolic markers in
T2D by other mechanisms than osteoglycin (16, 17).
Based on the current evidence, osteoglycin may be a
metabolically active molecule and impact on insulin action and
glucose homeostasis.
Regarding current knowledge, we wondered if osteoglycin
levels depends on pancreas function as T1D is characterized by
insulin depletion whereas T2D is a state of insulin resistance and
initially hyperinsulinemia. We hypothesized that osteoglycin
levels were not different between patients with T1D and T2D.
We aimed to examine osteoglycin levels in patients with T1D and
T2D and investigate potential associations between osteoglycin
and bone turnover markers, bone density measures, boneFrontiers in Endocrinology | www.frontiersin.org 2structural markers and metabolic parameters in respect to
pancreas dysfunction and insulin resistance.
METHODS
This cross-sectional study utilizes blood samples and bone scans
from previously published studies (4, 18). The STROBE statement
guideline for reports of cross-sectional studies was followed (19).
The trial was registered at ClinicalTrials.gov (NCT01870557).
Ethical Approval
The study protocol was approved by the Ethics Committee of the
Central Denmark Region (registration number: 1-10-72-5-13)
and follows the Declaration of Helsinki II. Informed consent was
obtained from all individuals in the trial.
Study Design
In the original study we included 200 participants and 197 were
examined. Three participants dropped out due to lack of time. We
excluded one participant in bisphosphonate treatment, two pre-
menopausal women, one patient with unmeasurable high
osteoglycin levels and three patients where measurements were
not obtained.190 patients with physician diagnosed diabetes
mellitus (97 T1D and 93 T2D) were consecutively included
from 2013-2014 at Aalborg (n=74) and Aarhus University
Hospitals (n=116) in a cross-sectional study. The physician
diagnosis of T1D is supported by measurement of antibodies if
there is uncertainty of diabetes type. All patients were > 50 years of
age and had a relatively stable HbA1c within the last six months (±
1% based on the DCCT scale). Furthermore, all patients had a
recent estimated glomerular filtration rate (eGFR) above 50 ml/
minute. The participants were not on weight loss- or ketogenic
diets. Physical activity was assessed by a questionnaire that has
previously been used to assess if physical activity is held constant
over time (20–23). Exclusion criteria were kidney disease defined
by eGFR below 50 ml/minute or macro albuminuria,
hyperthyroidism and hypothyroidism (treated hypothyroidism
with TSH within reference range were included), NYHA class
IV heart failure, and diseases or conditions affecting bone.
Potential participants treated with antiepileptics, glucocorticoids,
lithium, bone antiresorptive treatment, estrogen treatment, and
bone anabolic treatment were excluded. Pre-menopausal women
were excluded from the study. Information about diabetes related
complications, medication use, and lifestyle factors were collected
at baseline.
Blood Sample Analysis
Blood samples were collected in non-fasting conditions in the
morning (generally before 12 pm). Osteoglycin was analyzed by
the Enzyme-linked Immunosorbent Assay Kit (Human,
SEC688Hu) from Cloud-Clone Corp. (Katy, Tx, USA) as
described by the manufacturer. In brief, serum samples were
diluted 17.7 fold in 0.01 mol/L phosphate buffered saline (PBS),
pH 7.2 (Dulbecco PBS, Gibco # 14190-094) and analyzed in
duplicates. According to the manufacturer, no significant cross-
reactivity or interference between osteoglycin and analogues
have been observed, and the intra-assay coefficient of variationMarch 2021 | Volume 12 | Article 649718
Starup-Linde et al. Osteoglycin Levels in Diabetes Mellitus(CV) was < 10%, and inter-assay CV was < 12%. In our study,
intra-assay CV was 11.4% (N=196 serum duplicates), and inter-
assay was 17% (osteoglycin quality control) and 12.6% (serum
aliquot). In three subjects, the samples were missing or analysis
could not be conducted and one subject had immeasurable high
levels and was excluded from the analysis. The subject with
immeasurable high levels of osteoglycin did not differ from the
other participants in pharmaceutical use, age, BMI, glycemic
markers (p-glucose and HbA1c), and bone turnover markers. P-
C-terminal cross-linked telopeptide of type-I collagen (CTX), P-OC,
and P-procollagen type 1 amino terminal propeptide (P1NP) were
measured as single determinations on an automated Cobas analyzer
from Roche Diagnostics (Mannheim, Germany). P-sclerostin/S-
OPG (Biomedica, Vienna, Austria) and free non-OPG-bound S-
RANKL (Biomedica, Vienna, Austria) were measured as ELISA
double determinations. The analytical coefficients of variation were
according to the manufacturers as follows: CTX < 6%, P1NP < 4%,
OC < 2%, < 5%, Sclerostin < 10%, RANKL < 3%, OPG < 5%. All
bone turnover markers were analyzed on EDTA-plasma, except for
RANKL and osteoprotegerin (OPG) which were measured on
serum. Measurements were performed in clinical biochemical
laboratories accredited according to ISO 15189.
DXA and HRpQCT Scans
The scanning techniques have been described in detail elsewhere
(18). Trained staff performed dual energy x-ray absorptiometry
(DXA) measuring aBMD at the hip and lumbar spine. Two
Hologic Discovery scanners were used at Aarhus University
Hospital and two Lunar Prodigy scanners were used at Aalborg
University Hospital. The intra scanner precision CVs were 1% for
both Hologic Discovery and Lunar Prodigy scanners.
Patients at Aarhus University Hospital were examined by the
quantitative computed tomography (HRpQCT) scan (Xtreme
CT, Scanco Medical, Switzerland) at the radius and tibia. A
standard operating procedure was followed. Standard evaluation
analysis, finite element analysis, and cortical evaluation were
performed. To ensure reproducibility all scans and evaluations
were performed by J. Starup-Linde. The precision CVs were 0.7%
and 1% for the tibia and radius, respectively.
Data on Fractures
Fracture diagnoses were extracted from the Danish National
Hospital Discharge Register in the time period January 1, 1977 to
March 10, 2015. The registry was founded in 1977 and covers all
inpatient contacts from 1977 to 1994 and from 1995 also all
outpatient visits to hospitals, outpatient clinics, and emergency
rooms. Fractures were grouped as previous fractures and
incident fractures subsequent to the study. Vertebral fractures
were assessed by Vertebral Fracture Assessment (VFA) and x-ray
was performed for confirmation at Aarhus University Hospital
and by x-ray of thoracic and lumbar spine at Aalborg
University Hospital.
Statistical Analysis
Descriptive statistics were used to present patient characteristics
and the relation to biochemical bone turnover markers. STATA
8 was used to perform the analyses. Mean values of previouslyFrontiers in Endocrinology | www.frontiersin.org 3measured HbA1c of the last five years were calculated as the time
span between the first available measurements to the date of the
study blood sample. The mean HbA1c was used to explore
whether long-term glycemic control was associated with levels
of osteoglycin.
Unpaired t-test was performed to test for differences between
patients with T1D and T2D and linear regression analyses were
performed to detect associations between osteoglycin and glycemic
markers, bone turnover markers, and subject characteristics.
Bartlett’s test was used to determine if the t-test should be
performed with equal or unequal variances. Assumptions were
checked. Logistic regression analysis was performed to investigate
associations between osteoglycin and fractures.
The a priori hypothesis was that osteoglycin is associated with
bone turnover in patients with diabetes. A post hoc power
calculation would be highly dependent on the current study
results and this may not be valid, however we performed a
posthoc power calculation based on expected differences in
patients with T1D and T2D. We expected a difference of 500
ng/ml osteoglycin between T1D and T2D and assumed a sd of
500 thus 44 participants are needed.RESULTS
The study presents a post-hoc analysis from a previously
published study (4, 18).
Characteristics
Table 1 presents the participant characteristics. We report data
on 97 patients with T1D and 93 patients with T2D. Patients with
T1D were younger, had a lower BMI and longer diabetes
duration. The HbA1c of the participants ranged between 39
and 106 (mean 64 ± 9 mmol/mol) with no differences between
patients with T1D or T2D. Vitamin D levels were significantly
lower in patients with T2D (64.6 nmol/l vs. 74.2 nmol/l),
however for both groups the mean vitamin D levels were
within normal range. Also, bone formative markers (P-P1NP
and P-OC) were lower in patients with T1D. Data on physical
activity were missing in some subjects. We detected a lower level
of daily life physical activity in participants with T2D compared
to T1D, whereas there were no differences in physical activity
during sports and at work. Data on bone turnover marker, bone
structure and fracture differences between T1D and T2D have
previously been presented (4, 18).
Measurement of S-Osteoglycin and
Associations With Metabolic Markers
S-osteoglycin levels were not different between patients with T1D
and T2D (p=0.10). S-osteoglycin levels were positively associated
with BMI for the entire population, r=0.081 (95% CI 0.017; 0.144),
however the association became insignificant in sensitivity
analyses for T1D and T2D, respectively. Age, gender, diabetes
duration, microvascular complications, smoking, alcohol use and
insulin use were not associated with S-osteoglycin levels. Table 2
presents the results of the linear regression analysis between
osteoglycin and metabolic markers. Results for osteocalcin haveMarch 2021 | Volume 12 | Article 649718
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associations with metabolic markers (as plasma glucose and
HbA1c) and bone turnover markers (as CTX and P1NP) which
underline that the present study is powered to detect associations
(4, 18). Osteoglycin was not associated with the current HbA1c
level, mean HbA1c of previous 5 years, or random plasma glucose
level in neither patients with T1D nor T2D (p>0.05 for all) and
neither in analyses adjusted for age, BMI and gender. In sensitivity
analyses, similar results were revealed for patients with T1D and
T2D. The association between osteoglycin levels and the use of
oral antidiabetics, insulin and glucagon-like peptide-1 receptor
agonists (GLP-1) was investigated. Neither SU (23 users), insulin
(56 users) metformin (72 users) nor SGLT-2inhibitors (4 users)
were associated with osteoglycin levels (p>0.05 for all). Use of
GLP-1 receptor agonist (36 users) were associated with higher
levels of osteoglycin (8026, 95% CI 7262-8788 vs. 7041, 95% CI
6583-7500, p=0.0198) whereas use of DPP-IV inhibitors (11 users)Frontiers in Endocrinology | www.frontiersin.org 4were associated with lower levels of osteoglycin (7572, 95% CI
7125-8018vs. 6303, 95% CI 5445-7161, p=0.0472). We observed
no association between osteoglycin levels and measures of self-
reported physical activity.
Association of OsteoglycinWith BoneMarkers
Table 2 presents the results of the linear regression analysis
between S-osteoglycin, bone turnover markers, bone density and
structural markers. S-osteoglycin was not associated with the bone
turnover markers P-CTX, P-P1NP, P-OC, P-sclerostin, S-OPG or
S-RANKL levels and neither in analyses adjusted for age, BMI and
gender. S-osteoglycin levels were not associated with aBMD at the
hip, femur, lumbar spine or distal forearm. HRpQCT analyses of
the bone structure revealed no association with S-osteoglycin
levels neither for trabecular markers nor cortical markers. In
sensitivity analyses, similar results were revealed for patients
with T1D and T2D. Figure 1 displays a positive and significant
association between S-osteoglycin and BMI. We did not find any
significant correlations between S-osteoglycin and HbA1c (data
not shown). Multivariate analyses did not change any results.
Association With Prevalent Vertebral
Fractures and Incident Fractures
No associations between S-osteoglycin levels and prevalent
vertebral fractures, incident fractures, or previous fractures was
demonstrated using logistic regression analyses (p>0.05 for all).DISCUSSION
To our knowledge, this study is the first to report on S-osteoglycin
levels in patients with T1D. We found no difference in S-
osteoglycin levels between patients with T1D and T2D. We
found no evidence of an association between S-osteoglycin and
bone turnover markers, bone mineral density, bone structural





Characteristics mean (95% CI) mean (95% CI)
Age (years)a 60.8 (59.3;62.3) 65.2 (63.6;66.8)
BMI (kg/m2)a 25.8 (25.0;26.6) 30.7 (29.9;31.6)
Gender (male %) 60 (50;70) 63 (53;73)
Diabetes duration (years)*a 24.3 (21.7;26.8) 14.5 (12.9;16.1)
Microvascular complication (%) 48 (38;59) 46 (36;57)
Current smoker (%) 19 (11;26) 30 (21;40)
Alcohol intake (units/week)a 7 (5.5;8.5) 4.8 (3.4;6.2)
Insulin users (%)a 100 0.60 (0.50;0.70)
Biochemical parameters
Osteoglycin (ng/ml) 6.92 (6.47;7.37) 7.42 (7.01;7.83)
CTX (ng/ml) 0.22 (0.20;0.24) 0.19 (0.17;0.21)
Osteocalcina (ng/ml) 19.7 (18.4;20.9) 15.6 (14.4;16.9)
P1NPa (ng/ml) 41.3 (38.4;44.4) 36.0 (33.0;39.1)
Creatinine (mmol/l) 75.0 (71.7;78.3) 76.1 (72.3;79.9)
Vitamin Da (nmol/l) 74.2 (67.6;80.9) 64.6 (58.3;70.9)
HbA1c (mmol/mol) 64.7 (62.8;66.6) 63.5 (61.5;65.4)
Mean HbA1c of last five years (mmol/mol) 66.3 (64.6;67.9) 64.5 (62.9;66.1)
Random p-glucose* (mmol/l) 10.7 (9.71;11.6) 10.9 (10.1;11.7)
Physical activity of ½ hour (non-sports
fx gardening) (n=175)a
≥ 4 times per week (n) 34 30
2-3 times per week (n) 39 32
1 time per week (n) 11 8
2-3 times per month (n) 5 8
Less frequently (n) 5 7
Physical activity in sports of ½ hour
(n=167)
≥ 4 times per week (n) 9 10
2-3 times per week (n) 30 20
1 time per week (n) 22 16
2-3 times per month (n) 6 6
Less frequently (n) 18 30
Physical activity at work (n=162)
Office work or unemployed (n) 59 61
Some physical activity at work but no heavy
lifts (n)
8 8
Moderate physical activity at work with
heavy lifts (n)
13 9
Very physical active work with heavy lifts (n) 5 5ap < 0.05 between T1D and T2D *t-test with unequal variances due to Bartlett’s test. If n is
less than 5 for physical activity measures 5 is reported.TABLE 2 | Regression analysis of osteoglycin with bone and metabolic parameters.
Variable s-Osteoglycin
(coefficient and 95% CI)
Metabolic parameters
HbA1c (mmol/mol) 0.010 (-0.021;0.043)
Mean HbA1c of last five years (mmol/mol) 0.028 (-0.009;0.066)
Random p-glucose (mmol/l) -0.003 (-0.075;0.068)
Bone turnover and signaling markers
P-CTX (ng/ml) -0.234 (-3.11;2.65)
P-Osteocalcin (ng/ml) -0.034 (-0.082;0.014)
P-P1NP (ng/ml) -0.008 (-0.029;0.012)
P-Sclerostin (pmol/l) -0.001 (-0.010;0.010)
S-RANKL (pmol/l) -2.47(-7.61;2.67)
S-Osteoprotegerin (pmol/l) 0.036 (-0.107;0.180)
Bone density and structural markers
aBMD of the hip (n=187) (g/cm2) 1.041 (-0.991;3.003)
aBMD of the femur (n=187) (g/cm2) 0.442 (-1.850;2.735)
aBMD of the lumbar spine (n=189) (g/cm2) 0.429 (-1.303;2.162)
aBMD of the distal forearm (n=189) (g/cm2) 1.231 (-1.990;4.454)
Failure load radius (kN) -0.001 (-0.001;0.001)
Failure load tibia (kN) 0.001 (-0.001;0.001)
vBMD radius (n=111) (mg HA/cm3) -0.002 (-0.008;0.005)
vBMD tibia (n=113) (mg HA/cm3) -0.001 (-0.008;0.008)March 2021 | Volume 12 | Article 649718
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fractures. The association between BMI and S-osteoglycin for
the full group of participants may reflect that BMI and type 2
diabetes are linear covariates and we found no association between
BMI and S-osteoglycin in sensitivity analyses of patients with T1D
or T2D. Osteoglycin is hypothesized to be a novel marker of a
muscle, pancreas, and bone axis. This study includes diabetes
patients presumably with and without pancreatic dysfunction (i.e.
T1D and T2D) and so; we do not support the hypothesis.
Our study includes a large well-characterized population of
patients with T1D and T2D that contribute strength to the
results. The sample size made it possible to compare diabetes
types and adjust for relevant variables. We find no clear effects of
glucose-lowering drugs on osteoglycin levels. We suspect that the
opposite associations of DPP-IV and GLP-1 on osteoglycin levels
is a chance finding, although GLP-1 infusion has been shown to
recruit skeletal muscle in humans (24).
Blood samples were collected in a non-fasting state that may
affect serum levels of osteoglycin. P-P1NP and P-OC are
relatively stable markers independent of time of day or fasting
status, whereas P-CTX follows a circadian rhythm and is
suppressed by food intake (25, 26). A non-fasting state may
influence the variability of S-osteoglycin levels. In addition, it is
still unknown, whether the transcription and/or secretion of
osteoglycin exhibit a circadian rhythm. Thus, a limitation of the
presented results is the possible importance of sample collection
timing that may explain the insignificant results. Diabetes
mellitus is characterized as a disease with a disrupted fasting
state (27), and thus, even in fasting conditions diabetes patients
may present with elevated P-glucose levels. However, there are
no published studies on the effect of fasting versus non-fasting
state on S-osteoglycin levels in humans and neither before or
after insulin or glucose administration. Therefore, data on S-
osteoglycin levels before and after an oral glucose tolerance test
or meal as well as over time could provide further information.
The expression of osteoglycin is previously reported higher in
visceral adipose tissue samples compared to subcutaneous adiposeFrontiers in Endocrinology | www.frontiersin.org 5tissue and in particular, high in obese subjects compared to lean
subject (14). This supports our finding of a positive association
between BMI and osteoglycin. Another study found osteoglycin to
be negatively correlated with body fat in mice and BMI in humans
(12). However, this was limited by 19 subjects that all were severely
obese. In addition, the same study found increased white adipose
tissue fat mass and respiratory quotient in osteoglycin knockout
mice indicating metabolic flexibility and shift toward glucose
oxidation. During fasting and insulin infusion, the respiratory
quotient has been reported lower in healthy obese humans
compared to lean humans (28). Collectively, data on the
possible association between osteoglycin and BMI/fat mass in
humans and rodent seem conflicting. To reveal if any association
occur, we propose future research to measure osteoglycin in
adipose tissue biopsies as well as blood samples from lean
untreated and obese subjects in the fasting state.
The participants with T1D had a 10 year longer diabetes
duration compared to participants with T2D, however in T2D
the diagnosis seems delayed by 4-6 years (29). In the present study
we found no association between osteoglycin levels and diabetes
duration in neither patients with T1D or T2D. With longer
diabetes duration there may be an accumulation of AGE
products that is hypothesized to cause bone fragility (30). Bone
turnover markers are also decreased in the pre-diabetic state (31),
and it is unknown whether longer diabetes duration independent
of glycemic levels reduce bone turnover marker levels further.
S-osteoglycin levels have previously been associated with
fractures and low aBMD in patients with T2D (15), however
this study could not confirm these findings. This study used
similar assays as used in our study. In comparison the mentioned
study was performed on Japanese subjects with a slightly older
age, higher HbA1c and lower BMI compared to the T2D subjects
included in the present study (15).
Although mice with osteoglycin knockout display altered
metabolic and bone profile suggesting a bone-muscle- and
pancreas-axis (12, 13), we could not find any association between
osteoglycin and these markers in humans with diabetes. This may
be due to difference between mice and humans, or the alterations
observed in the bone and metabolic profile may only occur at very
low osteoglycin levels. Knowledge about the dynamics and
metabolization of osteoglycin are sparse. Moreover, there may be
counter-regulatory mechanisms to low S-osteoglycin levels in
humans which are not identified such as the circadian rhythm,
feeding, and exercise. In vitro and animal models are limited, and
very few studies have reported on osteoglycin in humans.
A bone pancreas axis has previously been proposed for OC, a
product of the osteoblasts, and especially its undercarboxylated
OC (ucOC) form. Based on mice models ucOC is suggested to
increase insulin production and insulin release from pancreatic b-
cells and conversely insulin is suggested to increase the production
of ucOC (32–34). However, in humans the evidence of an effect of
ucOC axis on glucose metabolism and insulin release is very
limited as an increase in ucOC by parathyroid hormone treatment
did not affect markers of energy metabolism (35). Neither were
there any difference in ucOC by an oral glucose tolerance test or
intravenous isoglycemic glucose infusion despite differentialFIGURE 1 | Association between BMI and osteoglycin.March 2021 | Volume 12 | Article 649718
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mice models and human studies for ucOC highlights that not all
finding in mice may translate into humans, which also may be the
case for osteoglycin.
The present study is limited by its cross-sectional nature. The
study cannot conclude on causality. Furthermore, we have no
healthy comparison group to neither T1D nor T2D. Moreover,
no reference range for S-osteoglycin levels in humans is known.
Thus, we cannot conclude whether the levels observed are high or
low. The current study was performed in a group of patients with
diabetes. Further perspectives would be to compare osteoglycin
between patients with diabetes and non-diabetic controls. However,
due to the relationship between muscle mass and osteoglycin such a
study would need to correct for muscle mass measured by sat whole
body DXA and/or muscle strength by say handgrip strength, but we
observed no association between osteoglycin levels and self-reported
physical activity. Trabecular bone score may improve fracture
detection in patients with T2D (37) and may be associated with
osteoglycin. However, we found no association between osteoglycin
and other bone structural measures in this study. Furthermore, we
had no data on 1,25 hydroxy vitamin D, but used 25 hydroxy
vitamin D as a surrogate marker as 1,25(OH)2D may be a biased
marker of true vitamin D status.
Impaired glucose metabolism is associated with compromised
bone integrity and the existence of increased risk of fractures
among patients with diabetes is increasingly recognized as an
important complication of both T1D and T2D and the risk seems
to increase with poor glycemic control (3, 38–41). Positive energy
balance paves the way of increase in body weight. To prevent
fractures, it is pivotal that the skeleton empowers the ability to
adjust by increasing its strength to match the higher mechanical
demand. Osteoglycin has been hypothesized to influence both
bone and metabolic markers and could be an important marker
or mediator of metabolic health, though the current study does
not support this hypothesis. However, current evidence on S-
osteoglycin levels in humans is limited and further research is
needed. There is a consensus on the fact that osteoglycin is
expressed and secreted from muscle cells and future studies
could focus on S-osteoglycin levels in human subjects with or
without diabetes mellitus as well as before and after exercise.
In conclusion, we did not find evidence supporting the existence
of an osteoglycin-bone-pancreas axis in humans with diabetes. In
this cross-sectional trial S-osteoglycin levels were similar in T1D and
T2D patients and did not correlate with glucose, HbA1c or any
other biochemical marker of bone turnover.Frontiers in Endocrinology | www.frontiersin.org 6DATA AVAILABILITY STATEMENT
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